89 related articles for article (PubMed ID: 37223993)
1. Impact of Direct-acting Antivirals on Hepatocellular Carcinoma and Mortality Among Medicaid Beneficiaries With Hepatitis C.
Jiang X; Song HJ; Chang CY; Wilson DL; Lo-Ciganic WH; Park H
Med Care; 2023 Aug; 61(8):505-513. PubMed ID: 37223993
[TBL] [Abstract][Full Text] [Related]
2. Treatment rates and factors associated with direct-acting antiviral therapy for insured patients with hepatitis C-related hepatocellular carcinoma - A real-world nationwide study.
Kam LY; Yeo YH; Ji F; Henry L; Cheung R; Nguyen MH
Aliment Pharmacol Ther; 2024 Feb; 59(3):350-360. PubMed ID: 37937485
[TBL] [Abstract][Full Text] [Related]
3. Assessing the impact of direct-acting antivirals on hepatitis C complications: a systematic review and meta-analysis.
Yew KC; Tan QR; Lim PC; Low WY; Lee CY
Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1421-1431. PubMed ID: 37728622
[TBL] [Abstract][Full Text] [Related]
4. Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C.
Lu M; Salgia R; Li J; Trudeau S; Rupp LB; Wu T; Daida YG; Schmidt MA; Gordon SC
J Viral Hepat; 2023 Sep; 30(9):746-755. PubMed ID: 37415492
[TBL] [Abstract][Full Text] [Related]
5. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study.
Wong YJ; Tran S; Huang CF; Hsu YC; Preda C; Toyoda H; Liu J; Jun DW; Landis C; Huang DQ; Gila A; Negoita L; Yasuda S; Tseng CH; Tsai PC; Uojima H; Nozaki A; Chuma M; Atsukawa M; Ishigami M; Itokawa N; Iio E; Lam CP; Watanabe T; Asai A; Yokohama K; Abe H; Enomoto M; Kawada N; Tamori A; Lee DH; Jun MJ; Do S; Vo DKH; Liu L; Li J; Ji F; Wang W; Li Y; Wang X; Guo F; Xu Q; Jing L; Ye Q; Pan H; Zhang J; Wen X; Wang Q; Ren H; Cai D; Shang J; Liu J; Lu C; Zang W; Li J; Niu J; Zhang M; Wu C; Huang R; Maeda M; Nakanishi A; Yeh ML; Chuang WL; Huang JF; Dai C; Ishikawa T; Takaguchi K; Senoh T; Trinh HN; Takahashi H; Eguchi Y; Quek SXZ; Haga H; Ogawa E; Wong G; Buti M; Fukunishi S; Ueno Y; Yuen MF; Tanaka Y; Lim SG; Cheung R; Yu ML; Nguyen MH
Hepatol Int; 2023 Oct; 17(5):1150-1161. PubMed ID: 37273170
[TBL] [Abstract][Full Text] [Related]
6. Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver Cirrhosis.
Hsieh YY; Chen WM; Chang KC; Chang TS; Hung CH; Yang YH; Tung SY; Wei KL; Shen CH; Wu CS; Ding YJ; Hu JH; Huang YT; Lin MH; Lu CK; Lin YH; Lin MS
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680293
[TBL] [Abstract][Full Text] [Related]
7. Prospective Comparison of Hepatocellular Carcinoma Behavior and Survival of Patients who Did or Did not Receive HCV Direct-Acting Antivirals.
El-Kassas M; Sayed H; Omran D; Eldahrouty AH; Elbaz T; Kamal E
Asian Pac J Cancer Prev; 2023 Feb; 24(2):597-605. PubMed ID: 36853310
[TBL] [Abstract][Full Text] [Related]
8. Controversies of Direct-Acting Antivirals in Hepatocellular Carcinoma.
Fatima I; Parikh ND; Likhitsup A
Surg Oncol Clin N Am; 2024 Jan; 33(1):43-58. PubMed ID: 37945144
[TBL] [Abstract][Full Text] [Related]
9. Changes in Use of Hepatitis C Direct-Acting Antivirals After Access Restrictions Were Eased by State Medicaid Programs.
Davey S; Costello K; Russo M; Davies S; Lalani HS; Kesselheim AS; Rome BN
JAMA Health Forum; 2024 Apr; 5(4):e240302. PubMed ID: 38578628
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of liver stiffness predicts complications in patients with HCV related cirrhosis treated with direct-acting antivirals.
Nicoletti A; Ainora ME; Cintoni M; Garcovich M; Funaro B; Pecere S; De Siena M; Santopaolo F; Ponziani FR; Riccardi L; Grieco A; Pompili M; Gasbarrini A; Zocco MA
Dig Liver Dis; 2023 Nov; 55(11):1472-1479. PubMed ID: 37142455
[TBL] [Abstract][Full Text] [Related]
11. Associations of Race and Ethnicity with Hepatocellular Carcinoma, Decompensation, and Mortality in US Veterans with Cirrhosis.
VoPham T; Cravero A; Feld LD; Green P; Feng Z; Berry K; Kim NJ; Vutien P; Mendoza JA; Ioannou GN
Cancer Epidemiol Biomarkers Prev; 2023 Aug; 32(8):1069-1078. PubMed ID: 37255388
[TBL] [Abstract][Full Text] [Related]
12. Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response.
Park JE; Nguyen VH; Tsai PC; Toyoda H; Leong J; Guy JE; Yeh ML; Huang CF; Yasuda S; Abe H; Hsu YC; Tseng CH; Liu J; Chen YL; Lin PY; Jun DW; Yoshimaru Y; Ogawa E; Ishigami M; Enomoto M; Tamori A; Uojima H; Wang XZ; Xu Q; Takahashi H; Eguchi Y; Inoue K; Huang DQ; Zhao WJ; Chuang WL; Dai CY; Huang JF; Barnett S; Maeda M; Cheung R; Landis C; Tanaka Y; Roberts LR; Schwartz ME; Kumada T; Yu ML; Nguyen MH
Aliment Pharmacol Ther; 2024 Mar; 59(6):742-751. PubMed ID: 38173278
[TBL] [Abstract][Full Text] [Related]
13. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
[TBL] [Abstract][Full Text] [Related]
14. Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program.
Lu MY; Huang CF; Hung CH; Tai CM; Mo LR; Kuo HT; Tseng KC; Lo CC; Bair MJ; Wang SJ; Huang JF; Yeh ML; Chen CT; Tsai MC; Huang CW; Lee PL; Yang TH; Huang YH; Chong LW; Chen CL; Yang CC; Yang SS; Cheng PN; Hsieh TY; Hu JT; Wu WC; Cheng CY; Chen GY; Zhou GX; Tsai WL; Kao CN; Lin CL; Wang CC; Lin TY; Lin CL; Su WW; Lee TH; Chang TS; Liu CJ; Dai CY; Kao JH; Lin HC; Chuang WL; Peng CY; Tsai CW; Chen CY; Yu ML;
Clin Mol Hepatol; 2024 Jan; 30(1):64-79. PubMed ID: 38195113
[TBL] [Abstract][Full Text] [Related]
15. Antiviral Treatment and Response are Associated With Lower Risk of Dementia Among Hepatitis C Virus-Infected Patients.
Tao MH; Gordon SC; Wu T; Trudeau S; Rupp LB; Gonzalez HC; Daida YG; Schmidt MA; Lu M
Am J Geriatr Psychiatry; 2024 May; 32(5):611-621. PubMed ID: 38199936
[TBL] [Abstract][Full Text] [Related]
16. Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales.
Shah SHBU; Alavi M; Hajarizadeh B; Matthews GV; Martinello M; Danta M; Amin J; Law MG; George J; Valerio H; Dore GJ
JHEP Rep; 2022 Oct; 4(10):100552. PubMed ID: 36119722
[TBL] [Abstract][Full Text] [Related]
17. Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study.
Hamill V; Wong S; Benselin J; Krajden M; Hayes PC; Mutimer D; Yu A; Dillon JF; Gelson W; Velásquez García HA; Yeung A; Johnson P; Barclay ST; Alvarez M; Toyoda H; Agarwal K; Fraser A; Bartlett S; Aldersley M; Bathgate A; Binka M; Richardson P; Morling JR; Ryder SD; MacDonald D; Hutchinson S; Barnes E; Guha IN; Irving WL; Janjua NZ; Innes H
BMJ; 2023 Aug; 382():e074001. PubMed ID: 37532284
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of direct-acting antivirals in patients with HCV decompensated cirrhosis: a systematic review and meta-analysis.
Jongraksak T; Chuncharunee A; Intaraprasong P; Tansawet A; Thakkinstian A; Sobhonslidsuk A
Front Med (Lausanne); 2023; 10():1295857. PubMed ID: 38093978
[TBL] [Abstract][Full Text] [Related]
19. [Research progress of direct-acting antiviral drugs in the treatment of chronic hepatitis C-related cirrhosis].
Zhao YF; Xu L; Mi YQ
Zhonghua Gan Zang Bing Za Zhi; 2024 Jan; 32(1):87-90. PubMed ID: 38320798
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus cure from direct-acting antivirals and mortality: Are people with and without a history of injection drug use in the same boat? (ANRS CO22 Hepather cohort).
Barré T; Bourlière M; Parlati L; Ramier C; Marcellin F; Protopopescu C; Di Beo V; Cagnot C; Dorival C; Nicol J; Zoulim F; Carrat F; Carrieri P;
Drug Alcohol Rev; 2024 Mar; 43(3):718-731. PubMed ID: 38133601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
